Earnshaw S, Brogan AJ, Brodtkorb T-H, Davis AE. Budget impact analysis II: applications and design issues. Presented at the 2021 Virtual ISPOR Short Course Program; December 6, 2021. Previously presented at the ISPOR 20th Annual International Meeting.
Hagberg K, Brodtkorb T-H. Patient-reported benefits of bone-anchored transfemoral prostheses as assessed by MedTech20 ©: a general outcome measure for medical products. Prosthet Orthot Int. 2021 Aug 1;45(4):355-61.
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Poster presented at the 2021 Virtual AMCP; April 12, 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting.
Brodtkorb T-H, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the U.S. Poster presented at the 2021 Virtual AMCP; April 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).
Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x
Earnshaw SR, Mauskopf JA, Mullins CD, Brodtkorb T-H. Budget impact analysis I: a 6-step approach. Presented at the ISPOR Virtual Short Course Progam; February 3, 2021. Previously presented at the 2015 ISPOR 18th Annual European Congress.
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.